Welcome to our dedicated page for NEOGEN SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neogen Corporation SEC filings document material events for an operating company focused on food safety and animal safety products. Recent 8-K filings cover quarterly results and financial condition, Regulation FD disclosures related to Petrifilm manufacturing validation, and exhibits containing earnings releases and business updates.
The company’s filings also record governance and leadership matters, including executive appointments and departures, compensatory arrangements, board committee assignments, annual meeting voting results, executive compensation votes, and auditor ratification. These disclosures provide formal records of Neogen’s public-company reporting, operating updates, governance structure and shareholder matters.
NEOGEN CORP Chief Legal Officer Stacey Jennifer Evans reported equity awards of common stock and stock options. She received 39,349 shares of Common Stock on May 1, 2026, valued at $9.53 per share, and now holds that amount directly.
On the same date she was granted 89,520 options to buy Common Stock at an exercise price of $9.53 per share, expiring on May 1, 2036. According to the footnote, these options and related RSUs vest in equal annual installments over three years, making this a multi-year compensation grant rather than an open-market trade.
Neogen Corp reports a Schedule 13G filing showing Vanguard Capital Management beneficially owns 11,164,628 shares of Common Stock, representing 5.13% of the class as of 03/31/2026.
The filing states Vanguard Capital Management has sole voting power over 1,599,582 shares and sole dispositive power over 11,164,628 shares. The report is signed by Ashley Grim on 04/30/2026 and notes holdings include shares held for Vanguard funds and managed accounts.
Neogen Corp reported beneficial ownership disclosed by Vanguard Portfolio Management. Vanguard Portfolio Management LLC reported beneficial ownership of 12,916,330 shares, representing 5.93% of Common Stock as of 03/31/2026. The filing states Vanguard exercises dispositive power through affiliated investment vehicles and lists sole voting power of 84,066 shares. The filing is signed by Ashley Grim on 04/29/2026.
Neogen Corporation filed a current report describing upcoming investor outreach and progress on product validation. The company plans to host two investor tours of its Petrifilm manufacturing facility in Lansing, Michigan on April 20, 2026 and April 21, 2026.
Neogen states it has successfully completed multiple operational qualifications for certain Petrifilm single kit units and is now proceeding with multiple performance qualifications for these SKUs as part of its broader validation efforts. This technical and validation update will be shared with investors during the facility tours.
NEOGEN CORP filed an insider ownership report for Chief Legal Officer Stacey Jennifer Evans. The filing lists her as an officer reporting person but shows no reported share transactions or derivative positions, and no current holdings entries, in the summarized data provided.
Neogen Corporation reported fiscal third quarter 2026 revenue of $211.2 million, down 4.4% from $221.0 million a year earlier, and posted a net loss of $17.0 million, or $(0.08) per diluted share. Food Safety sales grew 2.6% to $156.7 million, while Animal Safety revenue fell 20.1% to $54.5 million due to third‑party supplier issues.
On an adjusted basis, Neogen generated Adjusted EBITDA of $48.2 million with a 22.8% margin and Adjusted Net Income of $19.4 million, or $0.09 per share. The company raised its fiscal 2026 revenue outlook to $857–$860 million and maintained Adjusted EBITDA guidance of about $175 million.
Neogen also agreed to sell its global Genomics business to Zoetis for $160.0 million, expecting roughly $140.0 million of net cash proceeds to support a targeted net debt‑to‑Adjusted EBITDA ratio of less than three times by the end of calendar 2026. The Petrifilm manufacturing transition remains on track for completion by November 2026.
Neogen Corporation reported a leadership change in its legal function. The company announced that its Chief Legal and Administrative Officer, Amy Rocklin, will leave the company. Her departure is effective March 31, 2026, following the company’s announcement on March 30, 2026.
The Vanguard Group filed Amendment No. 15 to a Schedule 13G/A reporting 0 shares of Neogen Corp, representing 0% beneficial ownership. The amendment notes an internal realignment on January 12, 2026 under SEC Release No. 34-39538 that led certain Vanguard subsidiaries and business divisions to report holdings separately. The filing states those subsidiaries pursue the same investment strategies and that The Vanguard Group, Inc. no longer is deemed to beneficially own securities reported by those entities. The form lists the issuer address as 620 Lesher Place, Lansing, MI, and is signed by Ashley Grim on 03/27/2026.
Neogen Corporation’s common stock is reported as being beneficially owned by Gates Capital Management entities and Jeffrey L. Gates, who together report 8,385,534 shares, or 3.9% of the company’s common stock. All of these shares are shown with shared voting and shared dispositive power, and none with sole authority.
The ownership percentage is calculated using 217,525,981 shares outstanding as of November 30, 2025, as disclosed in Neogen’s Form 10-Q for that period. The reporting parties state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Neogen.